

1 **TITLE PAGE**

2

3 **Title: U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020–February 2022**

4 **Short Title: CDC support to international SARS-CoV-2 Serosurveys**

5

6 **Authors:**

7 Amen Ben Hamida<sup>1, 2, 3, 4\*</sup>, Myrna Charles<sup>2,3¶</sup>, Christopher Murrill<sup>2,4¶</sup>, Olga Henao<sup>1, 2¶</sup>, Kathleen Gallagher<sup>1,</sup>  
8 <sup>2¶</sup>.

9

10 **Affiliations:**

11 <sup>1</sup>: Division of Global Health Protection, U.S. CDC, Atlanta, GA, USA.

12 <sup>2</sup>: COVID-19 International Task Force, U.S. CDC, Atlanta, GA, USA.

13 <sup>3</sup>: Influenza Division, U.S CDC, Atlanta, GA, USA.

14 <sup>4</sup>: Global Immunization Division, U.S. CDC, Atlanta, GA, USA.

15

16 **Corresponding author:** [ABenHamida@cdc.gov](mailto:ABenHamida@cdc.gov) (ABH)

17

18 **Keywords:** SARS-CoV-2, COVID-19, Pandemic, Seroprevalence, serosurvey, low- and middle-income  
19 countries, U.S. CDC

20

21 **Abstract word count:** 300 / 300

22 **Manuscript word count:** 2,898 (no restriction)

23

## 24 **ABSTRACT**

25  
26 *SARS-CoV-2* seroprevalence surveys provide critical information to assess the burden of COVID-19,  
27 describe population immunity, and guide public health strategies. Early in the pandemic, most of these  
28 surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and  
29 middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention  
30 (CDC) is supporting serosurveys internationally.

31  
32 We conducted a descriptive analysis of international serosurveys supported by CDC during May 12,  
33 2020–February 28, 2022, using an internal tracker including data on the type of assistance provided,  
34 study design, population surveyed, laboratory testing performed, and status of implementation. Since  
35 the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI  
36 countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods,  
37 financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA  
38 and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews.  
39 Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7%  
40 sample healthcare workers, 7% sample other special populations (internally displaced persons, patients,  
41 students, and people living with HIV), and 18% assess multiple or other populations. These studies are in  
42 different stages of implementation, ranging from protocol development to dissemination of results.  
43 They are conducted under the leadership of local governments, who have ownership over the data, in  
44 collaboration with international partners. Thirty-four surveys rounds have completed data collection.

45  
46 CDC TA and FA of *SARS-CoV-2* seroprevalence surveys will enhance the knowledge of the COVID-19

47 pandemic in almost three dozen LMI countries. Support for these surveys should account for current  
48 limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting  
49 disease patterns over time, and helping understand antibody kinetics and correlates of protection.

## 50 INTRODUCTION

51  
52 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) —the virus responsible for coronavirus  
53 disease 2019 (COVID-19)— was first identified in December 2019 in Wuhan, China. After its rapid spread  
54 to 20 additional countries in the first six weeks, on January 30, 2020, the World Health Organization  
55 (WHO) declared COVID-19 a public health emergency of international concern (PHEIC, [\[1\]](#)). As of May  
56 2022, virtually all countries have been affected by COVID-19, resulting in more than 520 million COVID-  
57 19 confirmed cases and more than 6.2 million COVID-19-related deaths reported globally [\[2\]](#).

58  
59 Seroprevalence surveys are generally conducted to assess the prevalence of pathogen-specific  
60 antibodies in the serum and have been used extensively in the past to serve various public health  
61 purposes, including to a) assess the prevalence and incidence of infections (e.g., human  
62 immunodeficiency virus [HIV], hepatitis C and B viruses) [\[3-6\]](#); b) identify populations that are  
63 susceptible to infections [\[7\]](#); and c) inform and sustain models for disease control, elimination, or  
64 eradication (e.g., measles, rubella, diphtheria, poliomyelitis, and neonatal tetanus) [\[8-10\]](#).

65  
66 SARS-CoV-2 seroprevalence surveys complement case-surveillance data. Case-surveillance generates  
67 data that is needed to assess the burden and severity of disease and identify transmission hotspots.  
68 However, these case reports are generally incomplete because many infections are not recognized; for  
69 example, if a) an individual is asymptomatic and does not seek health care, b) testing is not available and  
70 accessible, or c) identified cases are not appropriately reported to the national public health disease  
71 surveillance system. It is in this context that SARS-CoV-2 seroprevalence surveys —which estimate the  
72 prevalence of SARS-CoV-2 antibodies within a specific population and thus provide a useful proxy to

73 assess previous exposure to and/or vaccination against *SARS-CoV-2*— were initiated. Data from these  
74 surveys provide critical information for decision-makers to estimate the true burden of disease, describe  
75 population immunity over place and time, identify still-at-risk groups, help assess vaccination coverage,  
76 and ultimately guide public health strategies [11].

77  
78 During the first year of the COVID-19 pandemic, most seroprevalence surveys were conducted within  
79 high-income countries, leaving a significant knowledge gap in low- and middle-income (LMI) countries.  
80 For example, among the 968 studies included in a systematic literature review of *SARS-CoV-2*  
81 seroprevalence studies conducted during 2020, only 23% were from LMI countries [11-13]. To address  
82 this gap, the U.S. Centers for Disease Prevention and Control (CDC) —along with multiple other  
83 international actors, including WHO— started supporting seroprevalence studies in LMI settings in mid-  
84 2020. In this paper, we describe CDC’s support of international seroprevalence surveys, define the  
85 purpose and characteristics of the supported studies, discuss challenges with implementation and  
86 propose possible steps moving forward to use seroprevalence data for public health action.

87

## 88 **MATERIALS AND METHODS**

89  
90 On January 20, 2020, CDC activated its Emergency Operations Center in response to the COVID-19  
91 pandemic to coordinate efforts to stop the transmission of *SARS-CoV-2* [14]. Consequently, an incident  
92 management structure was established, including the development and implementation of an incident  
93 action plan. Within the Incident Management System, an International Task Force, mostly consisting of  
94 CDC staff, was established to oversee CDC’s role in the global response, including support for the  
95 implementation and monitoring of *SARS-CoV-2* international seroprevalence studies. These studies were

96 funded mainly by the Coronavirus Aid, Relief, and Economic Security (CARES) Act, enacted on March 27,  
97 2020 [14-16].

98  
99 CDC-supported international seroprevalence studies are conducted under the leadership and guidance  
100 of local government agencies that request CDC support (e.g., Ministries of Health or national public  
101 health institutes) in close coordination with international stakeholders such as the WHO and Africa CDC.  
102 The national governmental agencies retain total ownership over generated seroprevalence data.  
103 However, limited and temporary access to seroprevalence data may be granted to CDC by the local  
104 authorities for a specific task (e.g., data analysis). Technical support is generally provided through CDC  
105 offices in country. It includes sharing of templates and guidance documents, assistance in protocol  
106 development, advice on sampling methodology and laboratory techniques, staff training, data analysis  
107 and interpretation, and dissemination of results.

108  
109 To ensure some degree of standardization, whenever possible, CDC staff worked closely with WHO, and  
110 encouraged countries to use the WHO UNITY protocol entitled “Population-based age-stratified  
111 seroepidemiological investigation protocol for COVID-19 infection.” The WHO UNITY protocol is part of a  
112 global seroepidemiological standardization initiative to increase evidence-based knowledge for action  
113 [17]. The WHO UNITY criteria include: using an age-stratified sample from the general population;  
114 following a cross-sectional, repeated cross-sectional, or a longitudinal survey design, including all  
115 individuals regardless of acute or prior SARS-CoV-2 infection; and using a validated SARS-CoV-2  
116 laboratory test kit with sensitivity  $\geq 90\%$  and specificity  $\geq 97\%$  [17]. Survey designs were modified, as  
117 appropriate, to accommodate country-specific needs.

118  
119 To support the implementation of these surveys, in December 2020 CDC initiated an international

120 seroprevalence community of practice (a virtual monthly group call) to facilitate communication  
121 between CDC headquarters and country office staff engaging in seroprevalence work. This community of  
122 practice provided an opportunity to discuss and exchange information on topics including sampling,  
123 testing, and survey methods and to share ongoing progress, lessons learned, and available  
124 seroprevalence data.

125  
126 In addition, we developed an Excel-based tracker for CDC-supported international seroprevalence  
127 surveys, where project staff could update status of protocol development and implementation for each  
128 survey. We reviewed information from the tracker and conducted a descriptive analysis of international  
129 serosurveys supported by CDC during May 12, 2020–February 28, 2022. Variables included in the  
130 analysis were: 1) type of assistance provided (e.g., only technical assistance, only financial assistance,  
131 both, informal technical review [as defined by a one-time request for technical review or consultation  
132 for a seroprevalence protocol that CDC is not actively engaged in]), 2) WHO region, 3) study design and  
133 population surveyed, 4) laboratory testing used, 5) status of survey implementation and 6) status of  
134 dissemination.

135  
136 This activity was reviewed by CDC, deemed not to be research (ID: 0900f3eb81de998d), and was  
137 conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46, 21 C.F.R.  
138 part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.). The same applies for all the  
139 serosurveys described in this manuscript that have received CDC funding and CDC technical assistance  
140 or in which CDC staff are listed as co-authors.

141

## 142 **RESULTS**

143

## 144 **Type of CDC Support and geographic distribution**

145 As of February 28, 2022, CDC has supported 72 COVID-19 international seroprevalence surveys,  
146 corresponding to 77 survey rounds in 35 LMI countries.

147

148 Among these survey rounds, the majority (61%) receive both technical and financial assistance from  
149 CDC, 30% receive technical assistance only, and 3% receive only financial assistance. Six percent were  
150 part of informal CDC reviews and technical assistance under the request of local authorities or external  
151 partners (Figure 1).


152

153 Most surveys (54%) were conducted within the WHO African region, followed by 18% in the Americas  
154 region, 13% within the South-East Asian region, 7% in the Western Pacific region, and 4% for each of the  
155 European and Eastern Mediterranean regions.

156

157 **Figure 1: CDC Support to SARS-CoV-2 international seroprevalence surveys as of February 28, 2022 (N=**  
158 **72 surveys / 77 survey rounds)**





159

160 Note: TA: Technical assistance. Greyed countries did not receive CDC assistance.

161 Map developed using QGIS Software and Natural Earth base layer [[18](#), [19](#)].

162

## 163 **Study design, population of interest, and WHO UNITY determination**

164 Among the 72 seroprevalence surveys, 69% are based on a cross-sectional design (84% of which are  
165 using a single round, while the remaining 16% are using multiple rounds), 19% involve following  
166 longitudinal cohorts, and 10% are part of the establishment of COVID-19-specific sentinel surveillance  
167 (or being integrated within an already existing surveillance system). The remaining 1% are using a hybrid  
168 design customized to the target population (Table 1).

169

170 Forty-seven percent of the surveys involve targeting the general population through household-based  
171 surveys, and 7% involve targeting the general population through other means (e.g., recruiting from  
172 community venues or using a convenience sample); 13% involve sampling pregnant women; 7% involve  
173 following health care worker cohorts; and 7% are conducted among other special populations including  
174 people living with HIV, persons who were displaced, and students. The remaining 18% target multiple or  
175 other populations (e.g., truck drivers).

176

177 Sixty-three percent of survey rounds have been assessed against WHO UNITY criteria. Among these, 79%  
178 involved methods aligned with the WHO UNITY criteria, and 21% did not.

179

## 180 **Laboratory procedures**

181 Among the 77 serosurvey rounds, 55% involved collecting blood via venipuncture, 25% involved using a  
182 finger stick and 5% involved using remnant samples from other studies or ongoing cohorts. Eight  
183 percent involved using multiple sample collection types, and 7% are yet to be determined. Seventeen  
184 percent involved using dried blood spots to store and transport specimens (Table 1).

185

186 The choice of antibody assays has been determined for 95% of serosurvey rounds. About half (55%)  
187 involved using an enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2 antibodies in  
188 serum, 20% involved using a multiplex assay, and 11% involved using a rapid test. The remaining 13%  
189 involved using multiple assays.

190

## 191 **Progress to date**

192 Progress varies across countries. By February 28, 2022, among the 77 survey rounds, 16% are in the  
193 stage of protocol development, 16% are in the stage of preparing for data collection, 17% are in the  
194 stage of data collection, 18% are in the stage of data analysis, 19% are in the stage of developing their  
195 deliverables, and 6% have their dissemination of results completed. The remaining 8% are either  
196 interrupted or CDC monitoring was discontinued (e.g., if CDC support was limited to an informal review)  
197 (Table 1).

198

199 **Table 1: Summary of CDC-supported international SARS-CoV-2 seroprevalence surveys (N= 72 surveys**  
 200 **/ 77 survey rounds)**

<b>Variables</b>	<b>N (%)</b>
<b>Type of Support (N=77 survey rounds)</b>	
Technical and financial assistance	47 (61%)
Technical assistance only	23 (30%)
Financial assistance only	2 (3%)
Informal review	5 (6%)
<b>Survey design (N=72 surveys)</b>	
Cross-sectional (one-time survey)	42 (58%)
Repeated cross-sectional	8 (11%)
Longitudinal cohort	14 (19%)
Sentinel surveillance system*	7 (10%)
Hybrid design**	1 (1%)
<b>Population surveyed (N=72 surveys)</b>	
General population — Household survey	34 (47%)
General population — Other	5 (7%)
Healthcare workers	5 (7%)
People living with HIV	3 (4%)
Persons who were displaced	1 (1%)
Patients	1 (1%)
Students	1 (1%)
Pregnant	9 (13%)
Other	3 (4%)
Multiple	10 (14%)
<b>WHO region (N=72 surveys)</b>	
Africa	39 (54%)
Americas	13 (18%)
South-East Asia	9 (13%)
Europea	3 (4%)
Eastern Mediterranean	3 (4%)
Western Pacific	5 (7%)
<b>Serologic testing (N=77 survey rounds)</b>	
ELISA	40 (52%)
Antibody Rapid Test	8 (10%)
Multiplex	15 (19%)
Other/multiple	9 (12%)
To be determined	5 (6%)
<b>Sample collection (N=77 survey rounds)</b>	
Venipuncture	42 (55%)
Finger Stick	19 (25%)
Remnant samples	4 (5%)
Multiple	6 (8%)
Not yet determined	6 (7%)

---

**Progress to date (N= 77 survey rounds)**

Protocol preparation and drafting	12 (16%)
Preparing for data collection	12 (16%)
Data collection ongoing	13 (17%)
Data analysis ongoing	14 (18%)
Drafting of deliverables ongoing	15 (19%)
Dissemination of results complete	5 (6%)
Serosurvey interrupted	2 (3%)
CDC monitoring discontinued	4 (5%)

201 Notes: \*Setting new sentinel surveillance systems (e.g., each month, recruiting the first 30 pregnant  
 202 women who are consulting at an ante-natal care clinic) or integrating seroprevalence within existing  
 203 ones (e.g., acute febrile illness sentinel surveillance system). \*\*Customized to the target population.  
 204 ELISA: enzyme-linked immunosorbent assay. Some variable percentages total 99% due to rounding.

205

206 **Dissemination of results**

207 To date, five manuscripts have been published. All five were cross-sectional, population-based surveys  
 208 conducted in Africa (Table 2). As of February 2022, at least 15 other manuscripts from 10 countries are  
 209 currently being drafted.

210

211 As shown in Table 2, among the published data, SARS-CoV-2 seroprevalence estimates obtained mostly  
 212 during the first year of pandemic ranged from 2.1% in Zambia (6 districts, July 2020) to 34.7% in Kenya  
 213 (Nairobi, November 2020) [20-24]. Infection to reported cases ratios —which is the ratio of the number  
 214 of persons with previous infections as detected by seroprevalence studies (seropositive), to the number  
 215 of COVID-19 cases detected by the surveillance system during the same period— ranged from 21:1 in  
 216 Ethiopia (Addis Ababa, June–July 2020) to 295:1 in Senegal (National, October–November 2020) [20-24].

217

218 **Table 2: Published CDC-supported SARS-CoV-2 international seroprevalence studies by February 28,**  
 219 **2022 (N= 5)**

---

Country	Geographic Scope	Design	Data Collection Period	Seroprevalence estimate	Infections to Cases Ratio	Reference
---------	------------------	--------	------------------------	-------------------------	---------------------------	-----------

---

<b>Ethiopia</b>	14 major urban areas	Cross-sectional, population-based	June 24–July 8, 2020	3.5% (95% CI= 3.2%–3.8%)	21:1 (in Addis Ababa)	Tadesse et al. [20]
<b>Kenya</b>	Nairobi	Cross-sectional, population-based	November 2020	34.7% (95% CI= 31.8–37.6)	42:1	Ngere et al. [21]
<b>Senegal</b>	National	Cross-sectional, population-based	October 24–November 26, 2020	28.4% (95% CI= 26.1–30.8)	295:1	Talla et al. [22]
<b>Sierra Leone</b>	National	Cross-sectional, population-based	March 2021	2.6% (95% CI= 1.9%–3.4%)	43:1	Barrie et al. [23]
<b>Zambia</b>	6 districts	Cross-sectional, population-based	July 4–27, 2020	Combined PCR and ELISA: 10.6% (95% CI= 7.3–13.9)  ELISA: 2.1% (95% CI= 1.1–3.1)	92:1	Mulenga et al. [24]

220 Notes: Infections to case ratio: Number of possible SARS-CoV-2 infections estimated based on the  
 221 seroprevalence survey, divided by the number of COVID-19 cases detected by the national surveillance  
 222 system by the mid-point of the data collection period. ELISA: enzyme-linked immunosorbent assay. PCR:  
 223 polymerase chain reaction. CI: confidence interval.

224

## 225 Discussion

226 To supplement ongoing COVID-19 surveillance efforts in countries and ensure a thorough understanding  
227 of disease prevalence in LMI settings, CDC currently supports more than 70 seroprevalence studies in 35  
228 countries. These surveys vary significantly in type of CDC support received, study design, the population  
229 surveyed, geographic distribution, laboratory method, and progress to date.

230

231 The heterogeneity in seroprevalence studies is expected given the varying situations and populations  
232 surveyed both within and between countries and has been observed by others conducting a systematic  
233 review to track *SARS-CoV-2* serosurveys globally [12, 13]. In June 2021, a Canadian team published a  
234 systematic literature review of seroprevalence studies conducted during 2020, which included 968  
235 unique serosurveys with significant heterogeneity noted [11]. In order to make sense of this diversity in  
236 seroprevalence studies and ensure comparability of results, several global initiatives have been  
237 launched including the Serotracker website, designed by the same Canadian team, which conducts a  
238 systematic live review of published *SARS-CoV-2* seroprevalence studies, and displays results in an  
239 automated live dashboard, allowing users to filter seroprevalence studies by several criteria including  
240 region, population of interest, date of data collection, and test type [12, 13]. Additional initiatives  
241 include the WHO UNITY approach and protocol templates for population-based seroprevalence surveys,  
242 which advocate for more standardization and more rigorous methods while conducting serosurveys [17,  
243 25]; and the WHO statement on the reporting of seroprevalence studies, which aims to standardize  
244 reporting of seroprevalence studies' results [26].

245

246 Five CDC-supported seroprevalence studies have been published to date; and at least 15 more had their  
247 results disseminated with MOH and are currently in the stage of developing their deliverables. All five  
248 published serosurveys were cross-sectional, population-based, and from countries in the WHO Africa  
249 region, with wide ranges in both SARS CoV-2 seroprevalence estimates (2.1% to 34.7%) and infection-to-

250 cases ratios (21:1 to 295:1) [20-24]. Of note, the previously mentioned systematic review and meta-  
251 analysis, including surveys conducted during 2020, estimated the median corrected SARS CoV-2  
252 seroprevalence to be 0.6% in Southeast Asia, East Asia, and Oceania; 4.1% in high-income countries;  
253 8.2% in North Africa and the Middle East; 10.6% in Latin America and the Caribbean; 12.2% in Central  
254 Europe, Eastern Europe, and Central Asia; 17.1% in South Asia; and 19.5% in Sub-Saharan Africa [11].  
255 The extreme variability in infection-to-case ratios from the CDC-supported surveys conducted in 2020 is  
256 consistent with those reported in the literature, from a median of 6:1 in Central Europe, Eastern Europe,  
257 and Central Asia to 217:1 in Southeast Asia, East Asia, and Oceania [11, 13]. This variability could be  
258 explained by different factors including differences in clinical presentation, availability of testing, and  
259 mitigation measures implemented in-countries.

260  
261 Seroprevalence results provide critical information for decision makers to guide ongoing public health  
262 strategies for the prevention and control of COVID-19. They allow for the assessment of the burden of  
263 disease (e.g., cumulative incidence and true case-to-fatality ratio), identification of hidden hotspots,  
264 quantification of the infection-to-case ratio, and estimation of vaccination coverage [11, 20-24]. When  
265 coupled with other surveillance, clinical, and epidemiologic data, data from these surveys can also help  
266 distinguish between a) a well-functioning surveillance system capturing most of the cases; b) a real gap  
267 in the ability of public health system to identify, diagnose, and report symptomatic cases; and c) a less  
268 severe clinical presentation which may lead to limited healthcare-seeking behavior.

269  
270 Supporting the implementation of international seroprevalence surveys has numerous ongoing and  
271 emerging challenges. These include the ever-evolving nature of the pandemic, changes in mitigation  
272 strategies and shifting data needs to inform the response, limited resources to support these and other  
273 epidemiologic endeavors globally, and competing country priorities. Additionally, there is a clear need

274 for serosurveys to adopt more efficient processes that allow for timelier implementation. These could  
275 include better integration with other ongoing surveillance or epidemiologic efforts; standardization of  
276 processes; and real-time analysis and dissemination of results.

277

278 Several factors have also challenged the interpretation and usefulness of seroprevalence surveys leading  
279 to a change over time in the questions these surveys can address. These include concerns about SARS-  
280 CoV-2 cross-reactivity with other pathogens, the implementation of COVID-19 vaccination campaigns,  
281 the emergence of new variants, reports of waning immunity, and un-defined correlates of protection  
282 (CoP).

283

284 Several reports have been shared suggesting possible antigenic cross-reactivity between *SARS-CoV-2*  
285 and other pathogens including *Plasmodium* species, Dengue viruses, and other human coronaviruses;  
286 possibly leading to a decreased specificity of *SARS-CoV-2* serologic testing and a higher level of false  
287 positive results, especially in the African region [27-32]. To help address this, CDC and WHO recommend  
288 using serologic tests that have been independently validated and conducting an in-country validation or  
289 verification whenever possible [33, 34].

290

291 Early in the pandemic and before the introduction of *SARS-CoV-2* vaccines, most seroprevalence survey  
292 objectives focused on assessing the true burden of disease to help identify gaps in national public health  
293 surveillance systems and identify at-risk populations [11, 17, 25]. The introduction of vaccines, critical in  
294 slowing the spread of the virus and decreasing severity of the disease, has created challenges in the  
295 design, implementation, and interpretation of *SARS-CoV-2* serosurveys. Testing algorithms involving the  
296 use of antibody assays with different targets (e.g. antibodies anti-nucleocapsid protein and antibodies  
297 anti-Spike protein) have been developed to help distinguish between natural and vaccine-induced



298 immunity for vaccines that only target Spike protein-derived antigens (e.g., current mRNA and viral  
299 vector vaccines) [35]. However, if the countries are using other vaccines or the survey design does not  
300 allow to distinguish between natural and vaccine-induced immunity, the objectives of seroprevalence  
301 surveys would be mostly limited to elucidating potentially at-risk populations and allocating scarce  
302 resources (vaccines) efficiently [35]. Additionally, mounting evidence of waning antibodies with both  
303 natural and vaccine-induced immunities challenges the ability to assess both the true burden of disease  
304 and vaccination coverage [36-39]. Of note, infection severity, timing of testing, and the choice of  
305 antibody assays all seem to significantly impact antibodies' detection over time [40]. CDC is currently  
306 working with international partners to address the statistical, epidemiologic, and laboratory  
307 considerations of vaccine introduction and to adapt seroprevalence protocols accordingly, based on  
308 WHO interim guidance and in-country specific needs and priorities.

309  
310 Finally, the question of correlates of protection (CoP) for SARS-CoV2 is not resolved. Several studies  
311 have documented an inverse relationship between neutralizing antibody levels and incidence of  
312 infection, and a correlation between these antibody levels and vaccine efficacy suggests a possible  
313 relative CoP against infection that is likely defined by quantitative thresholds [35, 41-44]. However, most  
314 serosurveys underway are using qualitative assays to assess circulating antibodies. Cellular immunity,  
315 which is generally more durable and likely to be integral to CoP, is generally not assessed in these  
316 surveys due to technical and cost challenges [35, 41].

317  
318 CDC technical assistance and financial support of SARS-CoV-2 international seroprevalence surveys  
319 contribute to strengthening local capacity to conduct epidemiologic surveillance and enhance the  
320 knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Considering constantly  
321 evolving challenges to implementation and interpretation of seroprevalence results two years into the

322 COVID-19 pandemic, there is a need for the global public health community to assess the best strategies  
323 for future SARS-CoV-2 seroprevalence efforts. These strategies could include developing a better  
324 understanding of antibody kinetics, identifying and forecasting epidemic patterns over time, and helping  
325 assess CoP. These objectives may be attainable by relying on prospective cohorts, integrating COVID-19  
326 sero-surveillance with surveillance of other pathogens, and introducing quantitative testing of binding  
327 and neutralizing antibodies. Support for international seroprevalence surveys can help understand  
328 patterns of transmission, guide public health interventions, allocate resources strategically, and  
329 ultimately control the spread of the pandemic.

330

## 331 **Disclaimer**

332 The findings and conclusions in this study are those of the author(s) and do not necessarily represent  
333 the views of the U.S. Centers for Disease Control and Prevention/Agency for Toxic Substances and  
334 Disease Registry.

335

## 336 **Acknowledgments**

337 U.S. CDC Countries offices involved in seroprevalence work; National Ministries of Public Health, CDCs,  
338 Institutes for Public health, and other implementing partners; U.S. CDC Division of Global Health  
339 Protection, Global Epidemiology, Laboratory, and Surveillance Branch, Surveillance and Information  
340 Systems Team and Laboratory Team; U.S. CDC International Task Force, Epidemiology and Laboratory  
341 Teams; WHO Seroprevalence Team; SeroTracker team; and Africa CDC Seroprevalence Team.

342

343

## 344 **References**

- 345 1. World Health Organization (WHO). COVID-19 Public Health Emergency of International Concern  
346 (PHEIC) Global research and innovation forum [Internet]. 2020 [updated 2020 February 12; cited 2021  
347 November 23]. Available from: [https://www.who.int/publications/m/item/covid-19-public-health-](https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum)  
348 [emergency-of-international-concern-\(pheic\)-global-research-and-innovation-forum](https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum).
- 349 2. World Health Organization (WHO). COVID-19 Explorer [Internet]. 2020 [updated 2022 May 18;  
350 cited 2022 May 18]. Available from: <https://worldhealthorg.shinyapps.io/covid/>.
- 351 3. Khokhar N, Gill ML, Malik GJ. General seroprevalence of hepatitis C and hepatitis B virus  
352 infections in population. J Coll Physicians Surg Pak. 2004;14(9):534-6.
- 353 4. Drain PK, Smith JS, Hughes JP, Halperin DT, Holmes KK. Correlates of National HIV  
354 Seroprevalence: An Ecologic Analysis of 122 Developing Countries. JAIDS Journal of Acquired Immune  
355 Deficiency Syndromes. 2004;35(4).
- 356 5. Abdool Karim Q, Abdool Karim SS, Singh B, Short R, Ngxongo S. Seroprevalence of HIV infection  
357 in rural South Africa. AIDS (London, England). 1992;6(12):1535-9.
- 358 6. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection:  
359 New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-9.
- 360 7. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis.  
361 Epidemiology and Infection. 2004;132(6):1005-22.
- 362 8. PachÓN I, Amela C, De Ory F. Age-specific seroprevalence of poliomyelitis, diphtheria and  
363 tetanus antibodies in Spain. Epidemiology and Infection. 2002;129(3):535-41.
- 364 9. McQuillan GM, Kruszon-Moran D, Hyde TB, Forghani B, Bellini W, Dayan GH. Seroprevalence of  
365 Measles Antibody in the US Population, 1999–2004. The Journal of infectious diseases.  
366 2007;196(10):1459-64.
- 367 10. Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges  
368 in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. The Journal of  
369 infectious diseases. 2018;218(3):355-64.

- 370 11. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-  
371 CoV-2 antibodies: A systematic review and meta-analysis. PloS one. 2021;16(6):e0252617.
- 372 12. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard [Internet]. 2020 [updated 2021  
373 November 10; cited 2021 November 24]. Available from: <https://serotracker.com/en/Explore>.
- 374 13. Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-CoV-  
375 2 seroprevalence dashboard. The Lancet Infectious diseases. 2021;21(4):e75-e6.
- 376 14. U.S. Centers for Disease Control and Prevention (CDC). CDC Emergency Operations Center  
377 Activations [Internet]. 2020 [updated January 20, 2020; cited November 26, 2021]. Available from:  
378 <https://emergency.cdc.gov/recentincidents/>.
- 379 15. Congress.gov. H.R.748 - CARES Act [Internet]. 2019 [updated March 27, 2020; cited November  
380 26, 2021]. Available from: <https://www.congress.gov/bill/116th-congress/house-bill/748>.
- 381 16. Bipartisan Policy Center. U.S. Leadership in the COVID-19 Pandemic Response: Global Health is  
382 U.S. Health [Internet]. 2020 [updated April 2020; cited November 26, 2021]. Available from:  
383 [https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC\\_Health\\_COVID19-](https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC_Health_COVID19-Pandemic-Response.pdf)  
384 [Pandemic-Response.pdf](https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2020/04/BPC_Health_COVID19-Pandemic-Response.pdf).
- 385 17. World Health Organization (WHO). Coronavirus disease (COVID-19) technical guidance: The  
386 Unity Studies: Early Investigation Protocols [Internet]. 2020 [updated 2020 May 26; cited 2021  
387 November 24]. Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations)  
388 [2019/technical-guidance/early-investigations](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations).
- 389 18. Natural Earth. Public Domain Map Dataset 2022 [cited May 25 2022]. Available from:  
390 <https://www.naturalearthdata.com/about/terms-of-use/>.
- 391 19. QGIS. A Free and Open Source Geographic Information System 2022 [cited May 25 2022].  
392 Available from: <https://qgis.org/en/site/index.html>.
- 393 20. Tadesse EB, Endris AA, Solomon H, Alayu M, Kebede A, Eshetu K, et al. Seroprevalence and risk  
394 factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during  
395 July 2020. International journal of infectious diseases : IJID : official publication of the International  
396 Society for Infectious Diseases. 2021;111:179-85.

- 397 21. Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High seroprevalence of  
398 SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya.  
399 International journal of infectious diseases : IJID : official publication of the International Society for  
400 Infectious Diseases. 2021;112:25-34.
- 401 22. Talla C, Loucoubar C, Roka JL, Barry A, Ndiay S, Diarra M, et al. Seroprevalence of Anti-SARS-CoV-  
402 2 Antibodies in Senegal: A National Population-Based Cross-Sectional Survey, between October and  
403 November 2020 [PrePrint]. 2021 [updated September 17, 2021; cited November 29, 2021]. Available  
404 from: <http://dx.doi.org/10.2139/ssrn.3925475>.
- 405 23. Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody prevalence  
406 in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey. *BMJ*  
407 *Glob Health*. 2021;6(11).
- 408 24. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-  
409 2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *The Lancet Global*  
410 *health*. 2021;9(6):e773-e81.
- 411 25. Bergeri I, Lewis HC, Subissi L, Nardone A, Valenciano M, Cheng B, et al. Early epidemiological  
412 investigations: World Health Organization UNITY protocols provide a standardized and timely  
413 international investigation framework during the COVID-19 pandemic. *Influenza and other respiratory*  
414 *viruses*. 2021;16(1), 7–13.
- 415 26. World Health Organization Seroepidemiology Technical Working G. ROSES-S: Statement from  
416 the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2. *Influenza*  
417 *and other respiratory viruses*. 2021;15(5):561-8.
- 418 27. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited  
419 Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin. *Emerging infectious diseases*.  
420 2021;27(1).
- 421 28. Emmerich P, Murawski C, Ehmen C, von Possel R, Pekarek N, Oestereich L, et al. Limited  
422 specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. *Trop Med*  
423 *Int Health*. 2021;26(6):621-31.

- 424 29. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential Antigenic Cross-  
425 reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.  
426 Clin Infect Dis. 2021;73(7):e2444-e9.
- 427 30. Gold JE, Baumgartl WH, Okyay RA, Licht WE, Fidel PL, Jr., Noverr MC, et al. Analysis of Measles-  
428 Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients. mBio. 2020;11(6).
- 429 31. Tso FY, Lidenge SJ, Pena PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-  
430 existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-  
431 2) in sub-Saharan Africa. International journal of infectious diseases : IJID : official publication of the  
432 International Society for Infectious Diseases. 2021;102:577-83.
- 433 32. Masyeni S, Santoso MS, Widyaningsih PD, Asmara DW, Nainu F, Harapan H, et al. Serological  
434 cross-reaction and coinfection of dengue and COVID-19 in Asia: Experience from Indonesia. International  
435 journal of infectious diseases : IJID : official publication of the International Society for Infectious  
436 Diseases. 2021;102:152-4.
- 437 33. NRL Science of Quality. Independent NRL contracted SARS-CoV-2 IVD assessments [Internet].  
438 2021 [updated November 29, 2021; cited November 29, 2021]. Available from:  
439 <https://www.nrlquality.org.au/who-covid-evaluations-summary-of-results>.
- 440 34. FIND The Global Alliance for Diagnostics. FIND Evaluation of SARS-CoV-2 Antibody Detection  
441 Tests [Internet]. 2021 [updated April 30, 2021; cited November 29, 2021]. Available from:  
442 <https://www.finddx.org/sarscov2-eval-antibody/>.
- 443 35. Duarte N, Yanes-Lane M, Arora RK, Bobrovitz N, Liu M, Bego MG, et al. Adapting Serosurveys for  
444 the SARS-CoV-2 Vaccine Era. Open forum infectious diseases. 2022;9(2):ofab632.
- 445 36. Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. The  
446 Lancet Infectious diseases. 2022;22(1):12-4.
- 447 37. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-  
448 CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).
- 449 38. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune  
450 responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162.

- 451 39. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, et al. Evaluation of Commercially  
452 Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications.  
453 *Emerging infectious diseases*. 2022;28(3):672-83.
- 454 40. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, et al. SARS-CoV-2 antibody  
455 magnitude and detectability are driven by disease severity, timing, and assay. *Science Advances*.  
456 2021;7(31):eabh3409.
- 457 41. Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. Does a  
458 humoral correlate of protection exist for SARS-CoV-2? A systematic review. *medRxiv*.  
459 2022:2022.01.21.22269667.
- 460 42. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for  
461 antibody as a protective correlate for COVID-19 vaccines. *Vaccine*. 2021;39(32):4423-8.
- 462 43. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody  
463 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*  
464 *Medicine*. 2021;27(7):1205-11.
- 465 44. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody  
466 titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-  
467 analysis. *The Lancet Microbe*. 2022;3(1):e52-e61.
- 468